SIGLEC Phase 2b Topline Results for AVD-104 in Geographic Atrophy

SIGLEC Phase 2b company-reported topline results show AVD-104 reduced geographic atrophy (GA) lesion growth and reported a favorable safety signal.

There is a substantial unmet need in dry AMD: advancing GA causes irreversible central retinal loss and functional decline. Slowing GA lesion growth is a clinically meaningful structural endpoint because it preserves retinal area that may support vision.

Treatment with AVD-104 yielded roughly a 31% reduction in GA lesion growth versus natural history over 12 months. Safety in the topline dataset was described as favorable. Conversion to neovascular AMD was low (≈2% in the monthly arm), no drug-related serious adverse events were reported, and the most common tolerability complaint was transient floaters. Reported follow-up did not identify retinal vasculitis or other severe ocular inflammatory events.

Larger cohorts and longer observation will better define rare or delayed risks.